Histologic patterns of liver injury induced by anti-PD-1 therapy

Dongwei Zhang¹,², John Hart³, Xianzhong Ding⁴, Xuchen Zhang⁵, Michael Feely⁶, Lindsay Yassan³, Lindsay Alpert³, Consuelo Soldevila-Pico⁶, Xuefeng Zhang⁷, Xiuli Liu¹, and Jinping Lai¹,⁸,*

¹Department of Pathology, Immunology and Laboratory of Medicine, University of Florida College of Medicine, Gainesville, FL, USA; ²Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA; ³Department of Pathology, University of Chicago Pritzker School of Medicine, Chicago, IL, USA; ⁴Department of Pathology and Laboratory of Medicine, Loyola University Medical Center, Maywood, IL, USA; ⁵Department of Pathology, Yale School of Medicine, New Haven, CT, USA; ⁶Department of Medicine, University of Florida College of Medicine, Gainesville, FL, USA; ⁷Department of Pathology, Duke University Medical Center, Durham, NC, USA; ⁸Department of Pathology, Kaiser Permanente Sacramento Medical Center, Sacramento, CA, USA

*Corresponding author. Department of Pathology, Kaiser Permanente Sacramento Medical Center, Sacramento, CA 95825, USA. Tel: 001-916-973-7288; Fax: 001-916-973-7283; Email: jinping.x.lai@kp.org

Abstract

Background: Nivolumab and pembrolizumab—two monoclonal antibodies that block human programmed cell death-1 (PD-1)—have been successfully used to treat patients with multiple advanced malignancies. The histologic patterns of hepatic toxicity induced by anti-PD-1 treatment have not been well studied and the aim of this study was to explore them.

Methods: Eight patients with advanced malignancies who were treated with either nivolumab or pembrolizumab were identified from five institutions. These patients had no history of underlying liver disease and a viral hepatitis panel was negative in all patients. Seven of eight patients exhibited mild to moderate gastrointestinal symptoms such as abdominal pain, fatigue, nausea, vomiting, and jaundice after anti-PD-1 treatment. Significant elevations in liver-chemistry tests were detected in all patients. Six cases (6/8) demonstrated an acute lobular hepatitis pattern of histologic injury. The remaining two cases showed different histologic patterns of injury: steatohepatitis with mild cholestasis (1/8) and pure acute cholestatic injury (1/8). No case showed typical features of autoimmune hepatitis. The liver function recovered in all eight cases after cessation of anti-PD-1 agents and with immunosuppressive therapy.

Conclusions: Our study suggests that screening patients for abnormal liver-function tests prior to anti-PD-1 therapy as well as periodic monitoring of liver-function tests are necessary to prevent severe liver injury. Rather than causing classical autoimmune hepatitis, PD-1 inhibitors appear to produce an immune-mediated nonspecific acute hepatitis. Drug cessation, without steroid therapy, may therefore be sufficient in some patients.

Key words: nivolumab; pembrolizumab; anti-PD-1; liver injury; histology; hepatitis
Introduction

Targeted immunotherapy as a potential treatment for cancer has been intensively studied over the past decade [1, 2]. Tumor cells often use multiple resistance mechanisms to evade the host immune system [3, 4]. Checkpoint proteins, such as programmed cell death-1 (PD-1) on T lymphocytes and PD-1 ligand (PD-L1) receptors on tumor cells, allow tumor cells to keep the host immune response in check [5, 6]. PD-1 is an inhibitory receptor expressed on activated T and B cells that limits the activity of T cells at a variety of stages of the immune response [7, 8]. Blocking the binding of PD-L1 to PD-1 with an immune checkpoint inhibitor (anti-PD-L1 or anti-PD-1 antibodies) can enhance antitumor responses and delay tumor growth [9, 10]. These antibodies have shown promising results in treating several types of malignancies in recent years [2].

Nivolumab (Opdivo) and pembrolizumab (Keytruda)—two human immunoglobulin G4 (IgG4) monoclonal antibodies targeting PD-1—are now used to treat patients with advanced tumors such as metastatic melanoma, non-small-cell lung cancer, squamous-cell carcinoma of the head and neck, urothelial carcinoma, Hodgkin lymphoma, and mismatch repair-deficient (dMMR) solid tumors [11–18]. Unfortunately, the use of these drugs can cause activating the immune system to attack normal organs, leading to a unique pattern of autoimmune-like/inflammatory side effects in some patients [19–21]. For example, liver-function abnormalities, such as increased alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase, and bilirubin, occurred in ≥10% of nivolumab-treated patients and at a higher occurrence rate than that in chemotherapy-treated patients [11, 16, 22]. The hepatitis induced by anti-PD-1 therapy has been reported as single case reports or small series [23, 24]. However, the hepatic histopathologic pattern of liver toxicity in these patients has not been well studied. This study aims to identify the histologic patterns of hepatic injury induced by anti-PD-1 treatment.

Patients and methods

Eight patients with advanced malignancies who were treated with nivolumab or pembrolizumab between 2016 and 2018 from the University of Florida College of Medicine (n = 2), University of Chicago Pritzker School of Medicine (n = 3), Loyola University Medical Center (n = 1), Yale School of Medicine (n = 1), and Duke University Medical Center (n = 1) were included in this study. Data on clinical presentation, medical history, laboratory tests, imaging, treatment, and patient outcomes were recorded. The patients did not have any previous history of underlying liver disease, except mild steatosis due to obesity in one patient. Liver-function tests were normal before treatment and viral hepatitis panels were negative before and after treatment. Liver biopsies were performed to evaluate the pattern of hepatic toxicity.

Results

Clinical characteristics

Clinical data are summarized in Table 1. Six patients were male and two were female. The mean age was 55 years (range, 42–69 years). Primary cancers included three metastatic melanomas, one metastatic pancreatic adenocarcinoma, one metastatic squamous-cell carcinoma of the head and neck, one...
ovarian high-grade serous carcinoma, one refractory Hodgkin lymphoma, and one glioblastoma. Six patients received a mean of three (range, 1–8) cycles of nivolumab and two patients received a mean of five (range, 4–6) cycles of pembrolizumab before liver biopsy. Seven out of eight patients exhibited mild to moderate gastrointestinal symptoms such as abdominal pain, fatigue, nausea, vomiting, and jaundice. Liver-function abnormalities such as elevated ALT, AST, and alkaline phosphatase were detected in all of the cases. ALT and AST were above five times the upper limit of normal in six out of eight patients. Elevated total bilirubin was detected in three cases. Imaging studies were performed in two patients and showed no biliary obstruction or intrahepatic dilatation.

**Histologic patterns of hepatic toxicity induced by anti-PD-1 therapy**

The time interval between the last drug administration and liver biopsy ranged from 23 days to 8 months. The histopathologic findings are summarized in Table 2. Acute lobular hepatitis was detected in six out of eight patients. The lobular inflammation was generally mild and consisted of a mixed inflammatory cell infiltrate with predominantly lymphocytes and rare plasma cells and eosinophils. Lobular spotty necrosis and acidophil bodies were seen in five cases (Figure 1A and B) and centrilobular confluent necrosis was seen in one case. In the case with lobular confluent necrosis, ANA became positive with a titer of 1:320. While a few plasma cells were seen in occasional portal tracts in this case, the portal chronic inflammation was still minimal and no interface hepatitis was identified. Immunohistochemical stains for cytomegalovirus and human herpes simplex types I/II as well as Epstein-Barr Early RNA (EBER) in situ hybridization were all negative.

No significant inflammation or fibrosis was identified in the portal tracts of these six cases with lobular hepatitis. Three cases showed mild large-droplet macrovesicular steatosis (5%, 15%, and 20%), without histologic evidence of steatohepatitis.

The two remaining cases exhibited different patterns of hepatic injury. One case demonstrated steatohepatitis with severe large-droplet macrovesicular steatosis present in 90% of hepatocytes, frequent ballooned hepatocytes (Figure 1C) with occasional Mallory-Denk bodies, and mild lobular inflammation (NAFLD Activity Score: steatosis 3, lobular inflammation 1, hepatocyte ballooning 2). A trichrome stain showed perportal and ‘chicken wire’ pericellular and perisinusoidal fibrosis (stage 2) (Figure 1D). Focal bile-duct injury and mild mixed canalicular and hepatocellular cholestasis (stage 2) (Figure 1D). Focal bile-duct injury and mild mixed canalicular and hepatocellular cholestasis (stage 2) (Figure 1D). Focal bile-duct injury and mild mixed canalicular and hepatocellular cholestasis (stage 2) (Figure 1D). Focal bile-duct injury and mild mixed canalicular and hepatocellular cholestasis (stage 2) (Figure 1D). Focal bile-duct injury and mild mixed canalicular and hepatocellular cholestasis (stage 2) (Figure 1D). Focal bile-duct injury and mild mixed canalicular and hepatocellular cholestasis (stage 2) (Figure 1D). Focal bile-duct injury and mild mixed canalicular and hepatocellular cholestasis (stage 2) (Figure 1D). Focal bile-duct injury and mild mixed canalicular and hepatocellular cholestasis (stage 2) (Figure 1D). Focal bile-duct injury and mild mixed canalicular and hepatocellular cholestasis (stage 2) (Figure 1D). Focal bile-duct injury and mild mixed canalicular and hepatocellular cholestasis (stage 2) (Figure 1D). Focal bile-duct injury and mild mixed canalicular and hepatocellular cholestasis (stage 2) (Figure 1D). Focal bile-duct injury and mild mixed canalicular and hepatocellular cholestasis (stage 2) (Figure 1D).

The final case showed a cholestatic pattern of injury featuring diffuse bile-duct injury in all of the portal tracts and mixed canalicular and hepatocellular cholestasis (Figure 1F). There was only mild portal and lobular inflammation. No bile-duct loss, periductal fibrosis, periportal cholate stasis, or fibrosis was identified. Immunohistochemical stains for cytomegalovirus and adenovirus were performed and were negative.

### Management and clinical outcomes

Nivolumab or pembrolizumab was discontinued in all cases because of worsening liver function. Additional immunosuppression
was also given to all of the patients: five patients received cortico-
steroids only, two patients received corticosteroids and mycophe-
nolate mofetil (cellcept), and one patient received corticosteroids
initially and then was switched to mycophenolate mofetil. All
patients had resolution of their symptoms and their transami-
nases improved significantly. Nivolumab was restarted in two
patients, and AST and ALT subsequently rose to a much higher
level compared with the level seen during their previous nivolu-
mab treatment. These two patients were subsequently treated
with cessation of nivolumab and initiation of corticosteroids, and
their abnormal liver functions eventually recovered. After a short
period of follow-up (6–8 months), six patients are still alive.
One patient died of advanced malignancy and the other patient
died of Achromobacter pneumonia and invasive aspergillosis.
There were no treatment-related deaths.

Discussion
In this report, we presented eight patients who were treated
with the anti-PD-1 agents nivolumab or pembrolizumab. The
clinical presentation, histopathologic findings in the liver, treat-
ment strategies, and outcomes were studied. Multiple patterns
of liver injury were observed in these patients, including acute
lobular hepatitis, steatohepatitis, and cholestatic injury. Even
though a few case reports and small case series have been pub-
lished to describe liver-biopsy findings of nivolumab-induced
liver injury [23, 24], our study provides a larger case series with
a more comprehensive analysis of the histopathological
features.

The approval of immune checkpoint inhibitors such as
anti-PD-1/anti-PD-L1 monoclonal antibodies has dramatically
changed the paradigm of cancer therapy. Unfortunately, check-
point-inhibitor therapy is associated with immune-mediated
side effects that result in collateral damage to normal tissues.
Checkpoint-inhibitor therapy-induced dermatitis, pneumonitis,
colitis, and hepatitis have been reported across several different
cancer types. While the toxicities induced by anti-PD-1 therapy
alone are rare and generally low-grade, rare severe toxicities,
including nivolumab-induced fulminant hepatic failure, have
been reported [25–27]. Fulminant and ultimately fatal orthotopic
liver-transplant organ rejection was also observed in two
pediatric patients with metastatic hepatocellular carcinoma af-
ter nivolumab administration [28]. In this study, we described
eight cases of hepatic toxicity induced by anti-PD-1 therapy.
Even though gastrointestinal symptoms and abnormal liver function were identified in these patients, fulminant hepatic failure was not observed. A consistent pattern of hepatic injury was also not seen historically.

The most common pattern of hepatic toxicity induced by anti-PD-1 therapy was acute lobular hepatitis with either spotty or centrlobular confluent necrosis (6/8). These findings support results from a recent study in which lobular hepatitis was a predominant pattern of liver injury induced by nivolumab or the anti-CTLA4 agent ipilimumab [24]. The lobular hepatitis in all of the patients was resolved but appeared to happen very slowly, as the inflammation and abundant ceroid-laden macrophages were observed up to 8 months after nivolumab cessation in one case. Interestingly, microgranuloma—a feature that was described previously in an ipilimumab-treated patient [29]—was detected in only one case in our study, suggesting that antitumor granulomatous reactions are uncommon in patients undergoing anti-PD-1 therapy. As shown in Tables 1 and 2, there is no association between the degree of acute lobular hepatitis and the number of cycles of anti-PD-1 therapy. And there is no time-related histologic difference among these cases of different time intervals.

Besides lobular hepatitis, a steatohepatitic pattern of injury was detected in one case in our study. This patient was obese but his liver-function test results were normal prior to nivolumab treatment. Liver biopsy was also performed prior to treatment in this patient and showed only mild macrovesicular steatosis (15%) without histological features of steatohepatitis or significant fibrosis. The patient developed steatohepatitis with stage 2 fibrosis 2 months after five cycles of nivolumab treatment, suggesting that steatohepatitis was truly induced by or associated with nivolumab treatment. Focal bile-duct injury with mild cholestasis was also present after nivolumab treatment in this patient. Interestingly, among cases with lobular hepatitis, mild steatosis was detected in three cases. It is unknown whether the steatosis was induced by anti-PD-1 therapy or was present prior to therapy in these cases. A pure cholestatic pattern of injury was observed in one case. There was bile-duct injury in all of the portal tracts as well as mixed canalicular and hepatocellular cholestasis in zone 3, with little associated inflammation. No bile-duct loss, cholate stasis, periportal fibrosis, or significant ductular reaction was detected, suggesting that this was an acute cholestatic pattern of injury.

Clinically, there was concern for autoimmune hepatitis in one case with confluent necrosis, as the patient’s ANA titer was within the normal range prior to nivolumab treatment but became positive with a titer of 1:320 after treatment. The patient was treated with corticosteroids and mycophenolate mofetil, and her transaminases improved significantly while on these therapies. However, no typical histologic feature of autoimmune hepatitis was identified in this case. Only a few plasma cells were present in some portal tracts, whereas the portal chronic inflammation was minimal and no interface hepatitis was identified. Autoimmune hepatitis is often considered in patients receiving anti-PD-1 treatment who develop abnormal liver-function tests because of the known immune-related side effects of these drugs, and this association also explains the frequent treatment of such patients with corticosteroids with or without immunosuppressant drugs. Based on our findings of the liver-injury patterns, no case showed typical features of autoimmune hepatitis, suggesting that corticosteroids plus immunosuppressant drugs may not be necessary in many patients who develop liver dysfunction while on anti-PD-1 therapy.

In summary, we found that nivolumab or pembrolizumab can cause acute lobular hepatitis as well as a cholestatic pattern of injury. Screening patients for abnormal liver-function tests prior to anti-PD-1 treatment and periodic monitoring may help to prevent severe liver injury. Liver biopsies play a key role in identifying the histologic patterns of hepatic toxicity induced by anti-PD-1 therapy. Our findings suggest that, rather than causing classical autoimmune hepatitis, PD-1 inhibitors appear to produce an immune-mediated but non-specific acute lobular hepatitis. The observations from this study challenge the present recommendation of using corticosteroids/immunosuppressive therapy to treat immune toxicity induced by checkpoint inhibitors. Instead, we suggest that simply stopping the drug may be sufficient, and that steroids and mycophenolate mofetil may not be necessary in many patients.

Authors’ contributions
D.Z. and J.L. designed and conceived of the study, and finalized the manuscript; J.H., X.D., X.Z., M.F., L.Y., L. A., C. S., X. Z., and X.L. analysed the data and reviewed the manuscript. All authors read and approved the final manuscript.

Funding
None.

Conflicts of interest
All authors declare that they have no conflicts of interest.

References
1. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol 2015;33:1974–82.
2. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252–64.
3. Dong H, Strome SE, Salomao DR et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8:793–800.
4. Blank C, Brown I, Peterson AC et al. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res 2004;64:1140–5.
5. Fife BT, Pauken KE, Eagar TN et al. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol 2009;10:1185–92.
6. Francisco LM, Salinas VH, Brown KE et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 2009;206:3015–29.
7. Ishida Y, Agata Y, Shibahara K et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. Embo J 1992;11:3887–95.
8. Freeman GJ, Long AJ, Iwai Y et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000;192:1027–34.
9. Brahmer JR, Drake CG, Wollner I et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010;28:3167–75.
10. Iwai Y, Ishida M, Tanaka Y et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 2002;99:12293–7.
11. Robert C, Long GV, Brady B et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372:320–30.
12. Topalian SL, Sznol M, McDermott DF et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014;32:1020–30.
13. Robert C, Ribas A, Wolchok JD et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014;384:1109–17.
14. Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015;373:1627–39.
15. Ferris RL, Blumenschein G, Fayette J et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 2016;375:1856–67.
16. Motzer RJ, Rini BI, McDermott DF et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol 2015;33:1430–7.
17. Ansell SM, Lesokhin AM, Borrello I et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med 2015;372:311–9.
18. Overman MJ, McDermott R, Leach JL et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 2017;18:1182–91.
19. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443–54.
20. Nishino M, Sholl LM, Hodi FS et al. Anti-PD-1-related pneumonitis during cancer immunotherapy. N Engl J Med 2015;373:288–90.
21. Geukes Foppen MH, Rozeman EA, van Wilpe S et al. Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. ESBO Open 2018;3:e000278.
22. McDermott DF, Drake CG, Sznol M et al. Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J Clin Oncol 2015;33:2013–20.
23. Simonelli M, Di Tommaso L, Baretti M et al. Pathological characterization of nivolumab-related liver injury in a patient with glioblastoma. Immunotherapy 2016;8:1363–9.
24. Zen Y, Yeh MM. Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury. Mod Pathol 2018;31:965–73.
25. Larkin J, Chaichian-Sileni V, Gonzalez R et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:23–34.
26. Robert C, Schachter J, Long GV et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015;372:2521–32.
27. Sarment S, Tara S. Acute liver failure from anti-PD-1 antibody nivolumab in a patient with metastatic lung squamous cell carcinoma. Austin Oncol 2016;1:1006.
28. Friend BD, Venick RS, McDiarmid SV et al. Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma. Pediatr Blood Cancer 2017;64:e26682.
29. Luke JJ, Lezcano C, Hodi FS et al. Antitumor granuloma formation by CD4+ T cells in a patient with rapidly progressive melanoma experiencing spiking fevers, neuropathy, and other immune-related toxicity after treatment with ipilimumab. JCO 2015;33:e32–5.